drugset / Trial / NCT01493882

Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma

NCT01493882

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting beta 2-agonist (LABA) and/or montelukast for at least 4 weeks.

Timeline

Start
2012-03
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-39758979 Small molecule 30 mg Oral
Subject JNJ-39758979 Small molecule 100 mg Oral
Subject JNJ-39758979 Small molecule 300 mg Oral

Indications